PATH Act Would Allow FDA To Approve Antibiotics For Limited Populations, Could Advance Antibiotic Drug Development

Health Affairs Blog: To Fight Antimicrobial Resistance, Allow FDA To Approve New Drugs For Limited Populations
Allan Coukell, senior director for health programs at the Pew Charitable Trust, discusses current global and U.S. efforts to prevent antibiotic drug resistance, as well as challenges to drug development. He examines the bipartisan “Promise for Antibiotics and Therapeutics for Health (PATH) Act [that] would allow the Food and Drug Administration (FDA) to approve antibiotics for limited populations of patients with serious and life-threatening bacterial infections that are resistant to current treatments” (4/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.